Form 4: Regeneron Director Michael S. Brown Reports Stock and Option Acquisition

Director Michael S. Brown reports acquisition of Regeneron stock and stock options.

Summary

• On January 2, 2025, Michael S. Brown, a director of Regeneron Pharmaceuticals, acquired 166 shares of common stock and 1,958 non-qualified stock options.
• The stock was acquired at a price of $0.0, representing time-based vesting restricted stock units.
• The non-qualified stock options have an exercise price of $719.37 and expire on January 2, 2035.
• Following these transactions, Brown directly owns 1,548 shares of common stock and 1,958 non-qualified stock options.
• Additionally, 5,000 shares are held indirectly in a trust for family members, and 6,162 shares are held indirectly by a SLAT.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock and option acquisitions by a director. While insider buying can be seen as positive, this is part of a compensation package and doesn't necessarily indicate a strong bullish signal.

Positives

• The acquisition of stock and options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry.
• The vesting schedules and exercise prices are typically structured to align management's interests with those of shareholders.
• Companies like Amgen, Pfizer, and Eli Lilly also use stock options and restricted stock units as part of their compensation packages.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It provides transparency regarding the director's holdings in the company.

Key Dates